Volume 191 - Issue 1
Hand–foot syndrome after treatment with docetaxel
Authors: Chitra Sivaramamoorthy, Eddy S Thientosapol and Martin H Tattersall
Med J Aust 2009; 191 (1): 40. || doi: 10.5694/j.1326-5377.2009.tb02675.x
Published online: 6 July 2009
Published online: 6 July 2009
A woman with metastatic breast cancer developed diarrhoea, vomiting, and hand and foot discomfort within about 10 days of ceasing therapy with capecitabine and starting docetaxel therapy. The palms of both hands and feet were inflamed and tender, with confluent blanching erythematous areas (Figure). Extensive desquamation occurred from Day 12 to Day 19 after admission, with return to normal skin by Day 30.
Hand–foot syndrome has been reported after therapy with various antineoplastic agents, most commonly cytarabine, liposomal doxorubicin, capecitabine, 5-fluorouracil, sorafenib and sunitinib. Increased metabolism of capecitabine in the palms may contribute to the local reaction;1 as may the concentration of docetaxel in eccrine glands in the palms and soles.2 Management involves stopping therapy with the implicated drug, analgesia, and preventing superinfection.
References
- Milano G, Etienne-Grimaldi MC, Mari M, et al. Candidate mechanisms for capecitabine-related hand–foot syndrome. Br J Clin Pharmacol 2008; 66: 88-95.
- Eich D, Scharffetter-Kochanek K, Eich HT, et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002; 25: 599-602. 0_i1091840
Challenges and Opportunities for Strong and Dynamic Foundations in the Australian Cancer Plan
Ashley M. Hopkins, Andrew Rowland, Natansh D. Modi, Ceara Rickard, Mark Haseloff, Norma B. Bulamu, Imogen Ramsey, Niranjan Bidargaddi, Ganessan Kichenadasse, Michael J. Sorich, Kalinda E. Griffiths, Aideen McInerney-Leo, David M. Roder, Raymond J. Chan
Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
Carolyn Ee, Ria Joseph, Elise Button, Stacey George, Makala Castelli, David Currow, Prue Cormie, Olivia Farrer, Michael Jefford, Nicolas H. Hart, Chad Y. Han, Deidre D. Morgan, Michael P. Osborn, Candice Oster, Joel Rhee, Anna Ugalde, Eric Yeung, Catherine Paterson
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
Erin L. Symonds, Billie Bonevski, Richard Edwards, Nathan J. Harrison, Sana Ishaque, Nicole M. Rankin, Sibel Saya, Renee J. Smith, Carolyn Ee
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum
Zayn Al-Timimi, Gem Chew, Martin Browne, Christiaan Mostert
From Ambition to Action: Closing Policy, Equity and Implementation Gaps in the Australian Cancer Plan's ‘Enhanced Consumer Experience’
Carla Thamm, Elise Button, Oluwaseyifunmi A. Agbejule, Reegan Knowles, Karen van Gorp, Mark B. Pinkham, Meinir Krishnasamy, Alexandra L. McCarthy, Raymond J. Chan